3 results
Primary: To demonstrate the efficacy of QGE031 relative to placebo at 12 weeks in patients withatopic dermatitis (AD) as assessed by Eczema Area and Severity Index (EASI).Secondary: efficacy assessed by Investigator Global Assessment (IGA, 12 weeks…
To assess the safety and tolerability profile of LJN452 and to determine the early hepatic response to different doses of LJN452 in patients with phenotypic non-alcoholic steatohepatitis (NASH). Data from this study will be used to support further…
To assess the safety, tolerability, pharmacodynamics and efficacy of two DLQ02 topical formulations in patients with plaque psoriasis. To assess systemic exposure of CsA and F6H8 after topical application.